ROZANOLIXIZUMAB (RYSTIGGO) INFUSION		version 2/27/2025		

Appointment Requests 	

	
	Interval	Defer Until	Duration	
	☐	Referral to IV Infusion Room	1 time a week	S	6 treatments	
		Status: Future, Expected: S, Expires: S+365, Clinic Performed
	Urgency of Scheduling: Routine		

Provider Communication 	

	
	Interval	Defer Until	Duration	
	☐	Provider communication	Every visit	S	Until discont'd	
		Dose according to body weight:
	< 50 kg = 420 mg; 
	>/= 50 to < 100 kg = 560 mg;
	>/= 100 kg = 840 mg.		

Nursing Orders 	

	
	Interval	Defer Until	Duration	
	☐	Nursing communication	Every visit	S	Until discont'd	
		Delay administration in patients with active infection until the infection is resolved. Immunization with live or live-attenuated vaccines is not recommended during treatment due to transient reduction in IgG levels during therapy.		
	☐	Nursing communication	Every visit	S	Until discont'd	
		1. Administer only via SUBQ infusion using an infusion pump.  
	2. Administer immediately after priming infusion set. 
	3. Choose an administration site on lower right or left part of abdomen below the navel; do not infuse where skin is bruised, hard, red, or tender; avoid areas with scars, stretch marks, or tattoos; rotate sites for subsequent administrations.		
	☐	Nursing communication	Every visit	S	Until discont'd	
		Monitor for signs/symptoms of hypersensitivity during administration and for 15 minutes after infusion is complete.		
	☐	Nursing communication	Every visit	S	Until discont'd	
		Do not flush infusion line, as infusion volume takes into account volume losses in line. Discard remaining solution.		

Less than 50 kg 	

	
	Interval	Defer Until	Duration	
	☐	rozanolixizumab-noli (RYSTIGGO) subcutaneous infusion 420 mg	1 time a week	S	6 treatments	
		420 mg, subcutaneous, Administer over: 15 Minutes, once, Starting when released
	Administer subcutaneously using an infusion pump set with a >26 gauge needle and tubing <=61 cm in length. Infuse for ~15 minutes at a constant flow rate up to 20 mL/hr. When the infusion is complete, do not flush the infusion line as the volume of infusion has been adjusted taking into account the losses in the line.		

Greater than or Equal to 50 kg to Less than 100 kg 	

	
	Interval	Defer Until	Duration	
	☐	rozanolixizumab-noli (RYSTIGGO) subcutaneous infusion 560 mg	1 time a week	S	6 treatments	
		560 mg, subcutaneous, Administer over: 15 Minutes, once, Starting when released
	Administer subcutaneously using an infusion pump set with a >26 gauge needle and tubing <=61 cm in length. Infuse for ~15 minutes at a constant flow rate up to 20 mL/hr. When the infusion is complete, do not flush the infusion line as the volume of infusion has been adjusted taking into account the losses in the line.		

Greater than or Equal to 100 kg 	

	
	Interval	Defer Until	Duration	
	☐	rozanolixizumab-noli (RYSTIGGO) subcutaneous infusion 840 mg	1 time a week	S	6 treatments	
		840 mg, subcutaneous, Administer over: 15 Minutes, once, Starting when released
	Administer subcutaneously using an infusion pump set with a >26 gauge needle and tubing <=61 cm in length. Infuse for ~15 minutes at a constant flow rate up to 20 mL/hr. When the infusion is complete, do not flush the infusion line as the volume of infusion has been adjusted taking into account the losses in the line.		

Hypersensitivity 	

	
	Interval	Defer Until	Duration	
	☐	acetaminophen (TYLENOL) tablet 650 mg	PRN	S	Until discont'd	
		650 mg, oral, every 4 hours PRN, mild pain (score 1-3), Starting when released, Until Discontinued
	Maximum of 4 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources).		
	☐	diphenhydrAMINE (BENADRYL) tablet 25 mg	PRN	S	Until discont'd	
		25 mg, oral, every 6 hours PRN, itching, Starting when released, Until Discontinued		
	☐	diphenhydrAMINE (BENADRYL) injection 25 mg	PRN	S	Until discont'd	
		25 mg, intravenous, once PRN, for minor infusion reaction, Starting when released, Until Discontinued		
	☐	diphenhydrAMINE (BENADRYL) injection 50 mg	PRN	S	Until discont'd	
		50 mg, intravenous, once PRN, for severe infusion reaction, Starting when released, Until Discontinued		
	☐	epINEPHrine (ADRENALIN) injection 1 mg/mL 0.5 mg	PRN	S	Until discont'd	
		0.5 mL, subcutaneous, once PRN, anaphylaxis, Starting when released, Until Discontinued		
	☐	hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	PRN	S	Until discont'd	
		100 mg, intravenous, once PRN, for infusion reaction, Starting when released, Until Discontinued		
	☐	promethazine (PHENERGAN) tablet 25 mg	PRN	S	Until discont'd	
		25 mg, oral, every 6 hours PRN, nausea, vomiting, Starting when released, Until Discontinued		
	☐	sodium chloride 0.9% infusion 250 mL	PRN	S	Until discont'd	
		250 mL, intravenous, once PRN, Hydration, Starting when released, Until Discontinued